Tonmya Side Effects
Tonmya (sublingual cyclobenzaprine) most commonly causes transient oral side effects including numbness of the mouth (oral hypoesthesia), abnormal taste, and tingling, along with systemic effects like drowsiness, dry mouth, and fatigue. 1
Most Common Side Effects
Oral/Local Effects (Very Common)
The sublingual formulation produces distinctive mouth-related side effects that are typically transient and self-limited:
- Oral hypoesthesia (reduced feeling in mouth): 23.4% vs 0.4% placebo 2
- Abnormal product taste: 11.3% vs 0.9% placebo 2
- Oral paresthesia (tingling): 6.9% vs 0.9% placebo 2
- Oral discomfort and pain 1
- Aphthous ulcers (canker sores) 1
These oral effects typically occur within minutes of administration and resolve within 60 minutes. To minimize these effects, patients should moisten their mouth with sips of water before taking the medication 1.
Systemic Effects (Common)
Anticholinergic Effects
Due to cyclobenzaprine's structural similarity to tricyclic antidepressants, it produces anticholinergic side effects 3:
These effects are particularly concerning in elderly patients and those with pre-existing conditions like glaucoma, urinary retention, or prostatic hypertrophy 3.
Serious Side Effects (Rare but Important)
Serotonin Syndrome
Life-threatening serotonin syndrome can occur, especially when combined with other serotonergic medications (MAO inhibitors, SSRIs, SNRIs, tramadol) 1. Symptoms include:
- Confusion, agitation, hallucinations
- Hyperthermia
- Tremor, muscle twitching
- Fast heartbeat, blood pressure changes
- Nausea, vomiting, diarrhea
- Muscle stiffness 1
Cardiovascular Effects
Cyclobenzaprine can cause tricyclic antidepressant-like cardiac effects 3:
The drug is contraindicated during acute myocardial infarction recovery and in patients with arrhythmias, heart block, or congestive heart failure 1.
Central Nervous System Effects
- Sedation and CNS depression - enhanced when combined with alcohol, barbiturates, or other CNS depressants 1
- Seizure risk - particularly when combined with tramadol 1
- Delirium and hyperkinetic movement disorders (rare) 4
The sedative effects are likely mediated through high-affinity noncompetitive antagonism at histamine H1 receptors 5.
Withdrawal Symptoms
With long-term use, discontinuation can cause withdrawal symptoms 3:
- Malaise
- Nausea
- Headache
These symptoms last 2-4 days but are not life-threatening. Tapering over 2-3 weeks can prevent withdrawal 3.
Comparative Safety Profile
In clinical trials, overall discontinuation rates were similar to placebo (RR 1.03), and no deaths were reported 6. The increased treatment-emergent adverse events (RR 1.41) were primarily driven by transient oral effects rather than serious systemic complications 6.
Importantly, when cyclobenzaprine was combined with ibuprofen for acute myofascial strain, CNS side effects occurred in 42% at 24 hours versus 18% with ibuprofen alone, without providing additional analgesic benefit 7. This suggests the CNS effects are clinically significant when the drug is used systemically.
Critical Drug Interactions
Absolute contraindications 1:
- MAO inhibitors (within 14 days)
- Hypersensitivity to cyclobenzaprine
Use with extreme caution 1:
- Other serotonergic drugs (SSRIs, SNRIs, triptans)
- Tramadol or meperidine
- CNS depressants (alcohol, barbiturates, benzodiazepines)
- Anticholinergic medications
- Bupropion
- Verapamil
Special Populations
- Elderly patients: Recommended dose is 2.8 mg due to increased sedative and hypotensive effects 1
- Hepatic impairment: Use 2.8 mg in mild impairment; not recommended in moderate or severe impairment 1
- Pregnancy: May cause neural tube defects; contraindicated from 2 weeks before conception through first trimester 1